Certain events bring about volatility that creates massive opportunities for traders on either side of the screen. That’s exactly what happened on Tuesday after a Berlin-based %Biotech company announced it plans to announce its third quarter 2022 financial results and business update on Thursday, November 10, 2022.
Traders tried to get ahead of this event during Tuesday’s session as shares of %ATAILifeSciences () were pushed up to $3.65/share (+23.73%) at the early session high.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.